SNWVSANUWAVE Health, Inc.
- GlobeNewswire
Sanuwave Announces Q2 FY2026 Financial Results
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 ...
- GlobeNewswire
Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results
EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will ...
- GlobeNewswire
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-cleared directed energy systems used in advanced ...
- GlobeNewswire
Sanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE ...
- GlobeNewswire
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating ...
- GlobeNewswire
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a ...
- GlobeNewswire
Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE) ...
- Analyst Upgrades
Roth Capital Reiterates Buy on SANUWAVE Health, Lowers Price Target to $47
Roth Capital analyst Kyle Bauser reiterates SANUWAVE Health with a Buy and lowers the price target from $53 to $47. ...
- GlobeNewswire
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time ...
- GlobeNewswire
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue ...
- GlobeNewswire
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased ...
- GlobeNewswire
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE ...
- GlobeNewswire
Sanuwave Announces Q3 FY2025 Financial Results
Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating ...
- GlobeNewswire
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a ...
- GlobeNewswire
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
CMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610 2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and ...
- SEC
SCHEDULE 13G Form - Statement of Beneficial Ownership by Certain Investors - SANUWAVE Health, Inc. (0001417663) (Subject)
Statement of Beneficial Ownership by Certain Investors ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
3 Form - Initial statement of beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Initial statement of beneficial ownership of securities ...
- GlobeNewswire
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - SANUWAVE Health, Inc. (0001417663) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
8-K Form - Current report, item 5.02 - SANUWAVE Health, Inc. (0001417663) (Filer)
Current report, item 5.02 ...